High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo
Anoumou Y. Dagnra,Nicole Vidal,Akovi Mensah,Akouda Patassi,Komi Aho,Mounerou Salou,Marjorie Monleau,Mireille Prince-David,Assétina Singo,Palokinam Pitché,Eric Delaporte,Martine Peeters +11 more
TLDR
The high number of resistant strains observed in Togo shows clearly that the emergence of HIV drug resistance is of increasing concern in countries where ART is now widely used, and can compromise the long-term success of first- and second-line ART.Abstract:
With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential challenges is the risk of emergence of ARV drug-resistant HIV strains. Our objective is to evaluate the virological failure and genotypic drug-resistance mutations in patients receiving first-line highly active antiretroviral therapy (HAART) in routine clinics that use the World Health Organization public health approach to monitor antiretroviral treatment (ART) in Togo.read more
Citations
More filters
Journal ArticleDOI
Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review
TL;DR: To improve the quality of patient care in global settings, recording HIV genotypes at baseline and at virologic failure with targeted non‐B subtype‐based point‐of‐care resistance assays and timely phasing out of resistance‐inducing ART regimens is recommended.
Journal ArticleDOI
Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting
Almoustapha Issiaka Maiga,D. B. Fofana,D. B. Fofana,Mamadou Cisse,Fodié Diallo,M. Y. Maiga,Hamar Alassane Traore,Issouf Alassane Maiga,Aliou Sylla,Dionke Fofana,Babafemi Taiwo,Robert L. Murphy,Christine Katlama,Anatole Tounkara,Vincent Calvez,Anne-Geneviève Marcelin +15 more
TL;DR: The need for governments and public health organizations to recommend the use of VL monitoring and also the availability of darunavir and raltegravir for third-line therapies in the context of limited-resource settings is underlines.
Journal ArticleDOI
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
David C Boettiger,Nguyen Vk,Nicolas Durier,Bui Hv,Heng Sim Bl,Iskandar Azwa,Matthew Law,K Ruxrungtham +7 more
TL;DR: Increased access to viral load monitoring to facilitate early detection of first-line ART failure and subsequent treatment switch is important for maximizing the durability of second-line therapy in Asia.
Journal ArticleDOI
Stock-outs of antiretroviral drugs and coping strategies used to prevent changes in treatment regimens in Kinondoni District, Tanzania: a cross-sectional study
Amani Thomas Mori,Joyce Owenya +1 more
TL;DR: Stock-out of antiretroviral drugs was reported in 16 out of the 20 clinics, causing 210 patients to change their ART regimens, during the 12 months preceding the survey, and inefficient supply systems, quantification problems and short expiry duration were cited as the main causes.
Journal ArticleDOI
Risk factors and mortality associated with resistance to first-line antiretroviral therapy: multicentric cross-sectional and longitudinal analyses
Loretxu Pinoges,Birgit Schramm,Elisabeth Poulet,Suna Balkan,Elisabeth Szumilin,Cecilia Ferreyra,Mar Pujades-Rodriguez +6 more
TL;DR: The findings underline the importance of optimal treatment adherence and adequate virological response monitoring and emphasize the need for resistance surveillance initiatives even in HIV programs achieving high virology suppression rates.
References
More filters
Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision.
TL;DR: These guidelines are primarily intended for use by national and regional HIV programme managers managers of nongovernmental organizations delivering HIV care services and other policy-makers who are involved in the scaling up of comprehensive HIV care and ART in resource-limited countries.
Journal ArticleDOI
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Paula Braitstein,Mwg Brinkhof,François Dabis,Mauro Schechter,Andrew Boulle,Paolo G. Miotti,Robin Wood,Christian Laurent,Eduardo Sprinz,Catherine Seyler,David R. Bangsberg,Eric Balestre,Jonathan A C Sterne,Margaret T May,Matthias Egger +14 more
TL;DR: Patients starting HAART in resource-poor settings have increased mortality rates in the first months on therapy, compared with those in developed countries, and timely diagnosis and assessment of treatment eligibility, coupled with free provision of HAART might reduce this excess mortality.
Journal ArticleDOI
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Charles F. Gilks,Siobhan Crowley,Rene Ekpini,Sandy Gove,Jos Perriens,Yves Souteyrand,Don Sutherland,Marco Vitoria,Teguest Guerma,Kevin M. De Cock +9 more
TL;DR: A public-health approach to antiretroviral therapy (ART) to enable scaling-up access to treatment for HIV-positive people in developing countries, recognising that the western model of specialist physician management and advanced laboratory monitoring is not feasible in resource-poor settings.
Journal ArticleDOI
Efficacy of Antiretroviral Therapy Programs in Resource-Poor Settings: A Meta-analysis of the Published Literature
TL;DR: ART treatment programs in resource-poor settings have efficacy rates similar to those reported for developed countries, and the provision of medications free of charge to the patient is associated with a significantly increased probability of virologic suppression at months 6 and 12 of ART.
Journal ArticleDOI
Darunavir: pharmacokinetics and drug interactions.
TL;DR: Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.